2022年WHO全球宫颈癌筛查覆盖率及HPV检测筛查估计
该综述与合成分析基于截至2024年1月31日的数据,估计2022年全球202个国家或地区30-49岁女性宫颈癌筛查覆盖率。结果显示,全球任何方法5年内筛查覆盖率为35%(95%CI 30-39),HPV检测5年内覆盖率仅8%(95%CI 6-9),中低收入国家与高收入国家差距显著。
要点
- 全球30-49岁女性5年内任何方法筛查覆盖率为35%,HPV检测覆盖率仅8%。
- 中低收入国家5年筛查覆盖率为26%,远低于高收入国家的74%。
- 既往5年内仅62国任何方法覆盖率达70%以上,仅5国HPV检测达此水平。
核心结论
- 尽管政策更新,全球宫颈癌总体筛查和HPV检测覆盖率仍远低于WHO 70%目标。
- 全球约五分之三30-49岁女性从未接受筛查,92%从未接受HPV检测。
- 扩大高性能HPV检测筛查并结合HPV疫苗接种对加速消除宫颈癌至关重要。
研究设计与样本
- 研究类型为综述与合成分析,估计2022年194个WHO成员国及8个关联国家或地区的宫颈癌筛查覆盖率。
- 使用截至2024年1月31日收集的项目和人群覆盖率数据,选取最能代表2022年筛查状况的来源。
- 初步估计经WHO国家磋商(2024年4-5月,补充回复至2025年7月)审核。
- HPV检测覆盖率基于各国各年份HPV检测筛查实施水平估计,并应用于2022年人口按区域和收入水平汇总。
主要发现
- 202个国家和地区中161个(80%)有宫颈癌筛查建议,其中92个(57%)推荐HPV检测筛查。
- 2022年30-49岁女性任何方法筛查覆盖率:既往1年19%(95%CI 15-22),既往3年31%(26-35),既往5年35%(30-39),曾筛查比例38%(33-43)。
- 5年筛查覆盖率中低收入国家为26%(21-31),高收入国家为74%(64-84)。
- 5年HPV检测筛查覆盖率全球为8%(6-9),高收入国家32%(25-40),中低收入国家2%(2-3)。
- 过去5年62个国家任何方法覆盖率达70%以上,5个国家HPV检测覆盖率达70%以上。
关键数值与推荐
- WHO消除宫颈癌战略目标为70%筛查覆盖率。
- 全球30-49岁女性5年内任何方法筛查覆盖率为35%(95%CI 30-39),HPV检测为8%(6-9)。
临床怎么用
- 应优先扩大HPV检测筛查在中低收入国家的实施,以缩小与高收入国家的差距。
- 需结合HPV疫苗接种和筛查扩围,加速实现WHO消除宫颈癌目标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Regularly updated global estimates are needed to monitor progress in cervical cancer screening, a key pillar of WHO's strategy to eliminate cervical cancer. We aimed to update estimates of cervical cancer screening coverage in 194 WHO member states and eight associated countries and territories for 2022, including the first global assessment of human papillomavirus (HPV) test-based screening adoption and roll-out. METHODS: In this review and synthetic analysis, we used an established method to estimate standardised cervical cancer screening coverage in 2022. We used programme and population-based coverage data collected up to Jan 31, 2024, selecting the sources considered most representative of each country or territory's screening situation in 2022. Preliminary estimates were reviewed through a WHO country consultation (April-May, 2024; with additional responses received until July 2025). HPV testing coverage was estimated based on HPV test-based screening implementation levels, by country and year. Estimates were applied to 2022 populations and aggregated by region and country-income level. FINDINGS: Cervical cancer screening recommendations were identified in 161 (80%) of 202 countries, with 92 (57%) of 161 countries recommending HPV test-based screening. By 2022, global coverage for women aged 30-49 years using any screening method (ie, cytology, HPV test, visual inspection with acetic acid, or combinations of these methods) was estimated at 19% (95% CI 15-22) for the previous year, 31% (26-35) in the previous 3 years, and 35% (30-39) in the previous 5 years; and 38% (33-43) of women had ever been screened. Disparities across regions and country-income levels were substantial: 5-year coverage was 26% (21-31) in low-income and middle-income countries, compared with 74% (64-84) in high-income countries. 5-year HPV test-based screening coverage was 8% (6-9) globally, 32% (25-40) in high-income countries, and 2% (2-3) in low-income and middle-income countries. In the past 5 years, 62 countries achieved more than 70% coverage with any screening method, and five countries with HPV testing. INTERPRETATION: Despite policy updates, overall and HPV-specific screening coverage remains far below WHO's 70% target. Three in five women aged 30-49 years worldwide have never been screened, and 92% have never received HPV testing, with substantial disparities across regions and country-income levels. Scaling up high-performance HPV test-based screening, alongside HPV vaccination, will be essential to accelerate cervical cancer elimination. FUNDING: WHO, Instituto de Salud Carlos III, European Regional Development Fund, Secretariat for Universities and Research, Government of Catalonia, and Horizon 2020.
引用
- Serrano B, Roura E, Alemany L, et al. 2022 WHO estimates for overall and human papillomavirus test-based cervical cancer screening coverage worldwide: a review and synthetic analysis. Lancet Glob Health. 2027. PMID: 42874626. doi:10.1016/j.langlo.2026.104044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。